RxDoctor Payments Data

James Ampadu, MD

Advanced Heart Failure and Transplant Cardiology · Columbia, SCNPI 1689916157

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 58.0% of the total. 2025 is the largest year on record at $59,733, 4.9 times the $12,287 reported in 2019.

$130,516in general payments, 2019–2025

Across 790 payments — averaging $165.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$76K
  • AstraZeneca$19K
  • Medtronic$12K
  • Bridgebio Pharma, Inc.$8K
  • Abbott$6K
  • Ancora Heart, Inc.$3K
  • plus $7K from 25 others
$80,940in research payments, 2019–2025

Across 28 payments — averaging $2890.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$53K
  • Medtronic$23K
  • Novartis$5K

What the payments were for

  • Consulting fees$17,66114%
  • Speaking & faculty fees$74,45957%
  • Grants$11,2509%
  • Travel & lodging$8,2596%
  • Food & beverage$18,77514%
  • Education$1130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,516 in reported general payments places this provider in the 85th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.

See all advanced heart failure and transplant cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$157,119
Medicare patients
553
Services billed
2,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis118$2,622,468
VyndaqelTafamidis Meglumine20$423,420
EntrestoSacubitril/Valsartan296$361,081
JardianceEmpagliflozin264$262,818
FarxigaDapagliflozin Propanediol185$173,123
EliquisApixaban106$102,444
CamzyosMavacamten13$101,983
VerquvoVericiguat36$42,398
KerendiaFinerenone28$32,077
XareltoRivaroxaban25$25,368
OzempicSemaglutide14$23,078
Bumetanide224$6,441
DapagliflozinDapagliflozin Propanediol12$5,956
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine17$5,045
Spironolactone374$3,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$880$3,148,332244 claims
NovartisEntresto$696$361,081296 claims
Boehringer IngelheimJardiance$511$262,818264 claims
AstraZenecaFarxiga$18,987$173,123185 claims
E.r. Squibb & Sons, L.L.C.Camzyos$280$101,98313 claims
MerckVerquvo$559$42,39836 claims
BayerKerendia$371$32,07728 claims
Johnson & JohnsonXarelto$79$25,36825 claims
Novo NordiskOzempic$173$23,07814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.

Other advanced heart failure and transplant cardiology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →